



# Factors associated with hepatitis C testing uptake among people who inject image & performance enhancing drugs.

Vivian Hope, Jim McVeigh, Emma Begley, Geoff Bates, Rachel Glass\*, Claire Edmundson\*, Ellen Heinsbroek\*, Joseph Kean, John Campbell<sup>‡</sup>, Gareth Morgan<sup>†</sup>, Dean Acreman<sup>†</sup> and Josie Smith<sup>†</sup>.

\* Public Health England;

<sup>†</sup> Public Health Wales;

*<sup>‡</sup> NHS Scotland* 

#### Introduction

- People who inject image and performance enhancing drugs (IPEDs) had been perceived as not being at high risk of hepatitis C virus infection<sup>1</sup>.
- Recent studies indicate the prevalence of antibodies to hepatitis C in this

### **Their infection risks**

 14% had ever shared a drugs vial (10% of those NSP recruited vs. 16% of those community recruited, p=0.084).



group is about 10-times that in the general population $^{2,3,4}$ .

Hepatitis C among people injecting IPEDs, UK.				
Study period, all England & Wales	Prevalence of antibodies to hepatitis C			
2010-2011	<b>5%</b> (20/395) <sup>2</sup>			
1998–2013	<b>4% (42/1,083)</b> <sup>3</sup>			
2012-2015	<b>5%</b> (27/564) <sup>4</sup>			

- Studies indicate alcohol consumption is high among those using IPEDs and the majority use C17 alpha alkylated steroids – both these can cause, or increase risk of, damage to the liver.
- Worryingly, the majority of hepatitis C virus infections among those injecting IPEDs remain undiagnosed<sup>4</sup>.



- 18% had ever reused their own needle-syringe (did not differ by recruitment setting).
- 2% had ever knowingly used someone else's needle-syringe (did not differ by recruitment setting).
- 89% were sexually active; 47% of those with 2+ partners had never or only occasionally used condoms during past 12 months.
- 5.7% had ever injected a psychoactive drug.

#### Uptake of hepatitis C testing

• A third (31%) had ever been tested for hepatitis C, and those tested were older (mean of 34 years vs. 32 years; *p*=0.039).



- 3.3% of those tested had used someone else's needle-syringe compared with 1.3% of those not tested (p=0.106).
- No difference in testing uptake by re-use of own needle-syringe or not, and sharing a vial or not.

#### **Factors associated with hepatitis C testing (multivariable analysis)**

	Factor	Tested HCV	l for V	Total	Adjusted Odds ratio	95% CI for Adjusted Odds Ratio
Sexuality	Heterosexual / Not reported	29%	162	552	1.00	
	LGB	68%	19	28	5.93	2.49-14.1
Ever injected a	No / Not reported	30%	163	547	1.00	
psychoactive drug	Yes	55%	18	33	2.27	1.04-4.98
Recruitment setting	In the community / Online	25%	110	440	1.00	
	In services	51%	71	140	3.08	2.03-4.68
Used peptides &	No / Not reported	23%	65	282	1.00	
associated growth hormones	Yes	39%	116	298	2.01	1.37-2.95
Ever imprisoned	No / Not reported	28%	136	479	1.00	
	Yes	45%	45	101	2.23	1.38-3.59

• We examined hepatitis C virus testing uptake using survey data.

# Method

☑

- People who had injected IPEDs across England, Scotland & Wales were surveyed during 2016 (<u>http://ipedinfo.co.uk/</u>).
- They were recruited from community settings, needle & syringe programmes and online. Those who agreed to participate self-completed a behavioural questionnaire.
- Factors associated with ever being tested for hepatitis C virus (self-reports) were examined using multivariable analysis.
- Potential missed testing opportunities were also explored by examining patterns of health service use.

## Limitations

- Self-reported data (for uptake of hepatitis C testing and year of the last test) may be subject to recall bias, though studies of people who inject drugs indicate that self-reports are reliable.
- Due to limited data on the size and nature of this population, we are currently unable to assess the representativeness of those recruited.
- Considering these issues, our findings need to be generalised with caution.

#### The sample

There were **580 participants**: their median age was 31 years; 97% were men; 4.4% identifying as lesbian, gay or bisexual (LGB); 17% had ever been imprisoned; and 4% of them were recruited through NSP and other services.

#### **Recency of testing & missed opportunities**

For three-fifths (60%) of those tested their most recent test was during **2014-2016**; for 29% it was during 2016 (among those who reported a year of last test).

Of those **never tested**, **50%** had **used a health service** where they could have been tested during the preceding year.

- 41% had used primary care;
- 10% had used NHS walk-in clinic;



9.3% had attended an Accident & Emergency department;

• 3.5% had used a sexual health (GUM) clinic.

### **Key Points & Conclusions**

- Two-thirds of those injecting IPEDs in this United Kingdom study had never been tested for hepatitis C infection. Testing for hepatitis C was associated with other risks; particularly the injection of psychoactive drugs and imprisonment. Half of those **not** tested had recently been in contact with a health service.
- Those recruited through services, principally needle & syringe programmes, were three times more likely to have been tested. Previous studies of people who inject IPEDs have focused recruitment on needle & syringe programmes, potentially over-estimating hepatitis C virus testing uptake and the proportion aware of their hepatitis C virus status.
- Targeted hepatitis C virus testing interventions are needed for those injecting IPEDs. Approaches to increasing testing uptake will need to reach those **not** using needle & syringe programmes, and those without a history of psychoactive drug injection or imprisonment.
- Further research is needed to inform intervention development and the best approaches for targeting interventions.

#### **References:**

- 1. Human Enhancement Drugs: The Emerging Challenges to Public Health. Evans-Brown et al. Liverpool, United Kingdom: North West Public Health Observatory; 2012. ISBN: 978-1-908929-01-3
- 2. Prevalence of, and risk factors for, HIV, hepatitis B and C infections among men who inject image and performance enhancing drugs: a cross-sectional study. Hope et al BMJ Open. 2013 Sep 12;3(9):e003207.
- 3. Risk of HIV and Hepatitis B & C Over Time Among Men Who Inject Image & Performance Enhancing Drugs in England and Wales: Results From Cross-Sectional Prevalence Surveys, 1992-2013. Hope, et al J Acquir Immune Defic Syndr.2016;71:331-7.
- 4. Low levels of hepatitis C diagnosis and testing uptake among people who inject image and performance enhancing drugs in England and Wales, 2012-15. Hope, *et al* **Drug Alcohol** Depend. 2017;179:83-86.